Free Trial

Mural Oncology Q4 Earnings Report

Mural Oncology logo
$1.25 +0.07 (+5.51%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mural Oncology EPS Results

Actual EPS
-$2.01
Consensus EPS
-$1.96
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$3.57

Mural Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mural Oncology Announcement Details

Quarter
Q4
Time
After Market Closes

Conference Call Resources

Remove Ads

Mural Oncology Earnings Headlines

HC Wainwright Weighs in on Mural Oncology Q1 Earnings
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
Mural Oncology price target lowered to $6 from $18 at H.C. Wainwright
See More Mural Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mural Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mural Oncology and other key companies, straight to your email.

About Mural Oncology

Mural Oncology (NASDAQ:MURA), a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

View Mural Oncology Profile

More Earnings Resources from MarketBeat